Bausch Health Companies (NYSE:BHC) Posts Earnings Results, Misses Estimates By $0.44 EPS

Bausch Health Companies (NYSE:BHC) released its earnings results on Wednesday. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44), Zacks reports. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. Bausch Health Companies updated its FY 2025 guidance to EPS.

Bausch Health Companies Stock Performance

Shares of BHC stock traded up $0.18 during mid-day trading on Wednesday, hitting $6.54. The company’s stock had a trading volume of 2,885,751 shares, compared to its average volume of 3,337,500. Bausch Health Companies has a 52-week low of $3.96 and a 52-week high of $11.46. The business has a 50-day moving average price of $7.39 and a 200 day moving average price of $7.47. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -13.63, a PEG ratio of 0.32 and a beta of 0.68.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BHC. Royal Bank of Canada lowered their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research note on Thursday, January 30th. Jefferies Financial Group restated a “hold” rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Finally, StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.